At the news
? NEUTRALIMPACT 2/10 SC 13D/A filed Nov 9, 2026 at 19:08 ET
Redmile Group filed Amendment No. 11 to its Schedule 13D solely to add Redmile Capital Offshore II Master Fund, Ltd. as a reporting person after its beneficial ownership surpassed 5% due to a change in Fate Therapeutics' outstanding share count. No transactions were executed, the aggregate stake remains at 14.99% (19,164,572 shares deemed beneficially owned), and no new demands or changes in purpose were disclosed.
- Redmile Group and related entities collectively own 19,164,572 shares of Fate Therapeutics, representing 14.99% of common stock.
- Redmile Capital Offshore II Master Fund, Ltd. was added as a reporting person after its beneficial ownership crossed 5% due to a change in the issuer's outstanding share count.
- No transactions were executed by the reporting persons since the prior filing (Amendment No. 10 on April 22, 2026).
- The filing states the purpose is unchanged; no new demands, strategic review, or board representation requests were disclosed.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access